Research programme: influenza therapy - Amyxa Pharmaceuticals

Drug Profile

Research programme: influenza therapy - Amyxa Pharmaceuticals

Alternative Names: APP-0206; CXF-Y2

Latest Information Update: 23 Jun 2009

Price : $50

At a glance

  • Originator Amyxa Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 23 Jun 2009 This programme is still active
  • 23 Jun 2009 Aphios Corporation is seeking development partners for the programme (http://www.aphios.com)
  • 24 Jan 2006 Preclinical trials in Influenza virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top